Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Other Non-Current Assets: 2019-2025

Historic Other Non-Current Assets for Biodesix (BDSX) over the last 5 years, with Sep 2025 value amounting to $7.5 million.

  • Biodesix's Other Non-Current Assets rose 12.85% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 12.85%. This contributed to the annual value of $7.3 million for FY2024, which is 5.85% up from last year.
  • Per Biodesix's latest filing, its Other Non-Current Assets stood at $7.5 million for Q3 2025, which was up 5.02% from $7.2 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Other Non-Current Assets registered a high of $7.5 million during Q3 2025, and its lowest value of $1.7 million during Q4 2021.
  • Its 3-year average for Other Non-Current Assets is $6.9 million, with a median of $7.0 million in 2023.
  • Over the last 5 years, Biodesix's Other Non-Current Assets had its largest YoY gain of 2,107.37% in 2021, and its largest YoY loss of 52.12% in 2021.
  • Quarterly analysis of 5 years shows Biodesix's Other Non-Current Assets stood at $1.7 million in 2021, then soared by 257.45% to $5.9 million in 2022, then rose by 15.80% to $6.9 million in 2023, then climbed by 5.85% to $7.3 million in 2024, then climbed by 12.85% to $7.5 million in 2025.
  • Its Other Non-Current Assets stands at $7.5 million for Q3 2025, versus $7.2 million for Q2 2025 and $7.3 million for Q1 2025.